查看文章

Inducing apoptosis in cancer cells is an important step for the successful treatment of cancer patients. Bcl‐2 is an antiapoptotic protein which determines apoptosis by interacting with proapoptotic members of the Bcl‐2 family. Exome sequencing has identified Bcl‐2 and Bax missense mutations in more than 40 cancer types. However, a little information is available about the functional impact of each Bcl‐2 and Bax mutation on the pathogenesis of cancer.

The mutational data from cancer tissues and cell lines were retrieved from the cBioPortal web resource. The 13 mutated Bcl‐2 and wild‐type Bax complexes with experimentally verified binding were identified from previous studies wherein, binding for all complexes was reportedly disrupted except one. Several protein–protein docking methods such as ClusPro, HDOCK, PatchDock, FireDock, InterEVDock2 and several mutation prediction …